390 related articles for article (PubMed ID: 30312731)
1. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
2. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
[TBL] [Abstract][Full Text] [Related]
3. Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.
Liu YN; Niu S; Chen WY; Zhang Q; Tao Y; Chen WH; Jiang KC; Chen X; Shi H; Liu A; Li J; Li Y; Lee YC; Zhang X; Huang J
Clin Cancer Res; 2019 Jul; 25(13):4128-4140. PubMed ID: 30962287
[TBL] [Abstract][Full Text] [Related]
4.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
Chen WY; Tsai YC; Siu MK; Yeh HL; Chen CL; Yin JJ; Huang J; Liu YN
Oncogene; 2017 Nov; 36(45):6213-6224. PubMed ID: 28692046
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
Tiwari R; Manzar N; Bhatia V; Yadav A; Nengroo MA; Datta D; Carskadon S; Gupta N; Sigouros M; Khani F; Poutanen M; Zoubeidi A; Beltran H; Palanisamy N; Ateeq B
Nat Commun; 2020 Jan; 11(1):384. PubMed ID: 31959826
[TBL] [Abstract][Full Text] [Related]
7. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
Weissenrieder JS; Reilly JE; Neighbors JD; Hohl RJ
Prostate; 2019 Jan; 79(1):21-30. PubMed ID: 30106164
[TBL] [Abstract][Full Text] [Related]
9. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance.
Chen WY; Wen YC; Lin SR; Yeh HL; Jiang KC; Chen WH; Lin YS; Zhang Q; Liew PL; Hsiao M; Huang J; Liu YN
Commun Biol; 2021 Jan; 4(1):22. PubMed ID: 33398073
[TBL] [Abstract][Full Text] [Related]
10. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
12. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
[TBL] [Abstract][Full Text] [Related]
14. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
15. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
16. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
17. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
18. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
19. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract][Full Text] [Related]
20. PEG10 is associated with treatment-induced neuroendocrine prostate cancer.
Kim S; Thaper D; Bidnur S; Toren P; Akamatsu S; Bishop JL; Colins C; Vahid S; Zoubeidi A
J Mol Endocrinol; 2019 Jul; 63(1):39-49. PubMed ID: 31013476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]